| Disease | THE PHARMACOKINETICS OF VPA WERE INVESTIGATED IN A RANDOMIZED, OPEN-LABEL, TWO-WAY CROSSOVER STUDY. SIX HEALTHY VOLUNTEERS RECEIVED THE FOLLOWING TREATMENTS IN A CROSSOVER DESIGN: (I) 1.2 G EXTRACT POWDER OF PAEONIA RADIX ONCE DAILY FOR 7 DAYS
AND ONE 200 MG VPA GASTRO-RESISTANT TABLET ON DAY 7 AND (II) ONE 200 MG VPA GASTRO-RESISTANT TABLET ALONE ON DAY 7. SERIAL PLASMA SAMPLES WERE OBTAINED ON DAY 7. THE MEAN MAXINUM PLASMA CONCENTRATION OF VPA WAS ATTAINED AT WITHIN 6 HR AFTER ORAL
ADMINISTRATION OF VPA IN COMBINATION WITH PR. THE PLASMA LEVEL OF VPA DECLINED WITH A HALF-LIFE OF 11.71 AND 11.91 H, RESPECTIVELY. NO STATISTICALLY SIGNIFICANT DIFFERENCE WAS OBTAINED IN ANY OF THE PHARMACOKINETIC PARAMETERS (TMAX, CMAX,
AUC, T1/2, MRT, CL/F AND VD/F) OF VPA BETWEEN THE TWO TREATMENTS. ALSO, THERE WAS NO SIGNIFICANT DIFFERENCE IN THE PROTEIN BINIDNG RATES OF VPA. PR DID NOT SIGNIFICANTLY AFFECT THE ABSORPTION, DISTRIBUTION, METABOLISM AND ELIMINATION OF VPA
IN HEALTHY VOLUNTEERS. |